- Home
- CLDX vs WGS Comparison
CLDX vs WGS Comparison
Compare CLDX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- WGS
- Stock Information
- Founded
- CLDX 1983
- WGS 2017
- Country
- CLDX United States
- WGS United States
- Employees
- CLDX N/A
- WGS N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- CLDX Health Care
- WGS Technology
- Exchange
- CLDX Nasdaq
- WGS Nasdaq
- Market Cap
- CLDX 1.7B
- WGS 2.0B
- IPO Year
- CLDX 2008
- WGS N/A
- Fundamental
- Price
- CLDX $22.46
- WGS $95.83
- Analyst Decision
- CLDX Buy
- WGS Strong Buy
- Analyst Count
- CLDX 8
- WGS 5
- Target Price
- CLDX $61.86
- WGS $82.60
- AVG Volume (30 Days)
- CLDX 774.1K
- WGS 1.5M
- Earning Date
- CLDX 03-04-2025
- WGS 02-18-2025
- Dividend Yield
- CLDX N/A
- WGS N/A
- EPS Growth
- CLDX N/A
- WGS N/A
- EPS
- CLDX N/A
- WGS N/A
- Revenue
- CLDX $9,976,000.00
- WGS $305,450,000.00
- Revenue This Year
- CLDX N/A
- WGS $44.70
- Revenue Next Year
- CLDX N/A
- WGS $16.73
- P/E Ratio
- CLDX N/A
- WGS N/A
- Revenue Growth
- CLDX 128.55
- WGS 50.79
- 52 Week Low
- CLDX $20.91
- WGS $7.16
- 52 Week High
- CLDX $53.18
- WGS $115.60
- Technical
- Relative Strength Index (RSI)
- CLDX 42.55
- WGS 59.30
- Support Level
- CLDX $22.38
- WGS $65.10
- Resistance Level
- CLDX $23.69
- WGS $115.60
- Average True Range (ATR)
- CLDX 1.07
- WGS 9.03
- MACD
- CLDX 0.03
- WGS 3.96
- Stochastic Oscillator
- CLDX 44.67
- WGS 65.30
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.